Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 32 n° 259

Bioasis Announces Stock Option Grants

Posted by fidest press agency su sabato, 20 luglio 2019

Bioasis Technologies Inc. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™ platform technology for the delivery of therapeutics across the blood-brain barrier (“BBB”) and the treatment of central nervous system (“CNS”) disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases, today announced that it has granted stock options to acquire a total of 1,576,240 common shares at a price of $0.27 per share to directors and officers of the company, including 510,000 options granted to Mario Saltarelli, who joined the board as a new director in May 2019 and 391,240 options granted to Deborah Rathjen, President & Chief Executive Officer, in lieu of cash compensation. The options granted to Dr. Rathjen are immediately exercisable, the options granted to Dr. Saltarelli vest over a period of 12 months from the date of grant and the rest of the options, all of which were issued to officers of the company, vest over a period of five years from the date of grant. All of the options expire five years from the date of the grant and are governed by the terms of the company’s stock option plan.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: